Ten Years of Vildagliptin
After many years of limited therapeutic opportunities, the treatment of type 2 diabetes has become more target and pathophysiologically driven. A typical example is represented by the development of the dipeptidyl peptidase-4 (DPP-4) inhibitors, allowing for more physiological regulation of the endocrine pancreas and leading to a previously unmet risk-to-benefit balance. Vildagliptin, one of the earliest DPP-4 inhibitors, has been tested across the entire spectrum of type 2 diabetes and has been in clinical use for 20 years. This publication critically reviews the main steps in the clinical development of this agent.
Type 2 diabetes, DPP-4 inhibitors, vildagliptin
Stefano Del Prato has received research support from AstraZeneca,
MSD, Novartis and Boehringer Ingelheim, and consultancy fees from AstraZeneca,
Boehringer Ingelheim, Eli Lilly, GSK, MSD, Novartis, Novo Nordisk, Sanofi, Servier
and Takeda. This article is a short opinion piece and has not been submitted to
external peer reviewers but was reviewed by a member of the Editorial Board
Stefano Del Prato, Department of Clinical and
Experimental Medicine University of Pisa, Via Roma 67,. I-56100 Pisa, Italy.
The publication of this article was supported by Novartis Pharma AG.
This article is published under the Creative Commons Attribution
Noncommercial License, which permits any non-commercial use, distribution,
adaptation and reproduction provided the original author(s) and source are given
Share this Article
Related Content In Diabetes
Foreword: touchREVIEWS in Endocrinology 19.1
Welcome to the latest edition of touchREVIEWS in Endocrinology. In this edition we feature a range of review, case report and original research articles that highlight some key developments in our understanding and management of endocrinological disease. We start with a focus on diabetes. An editorial from Bhattacharya and Kalra gives an overview of the […]
Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
touchREVIEWS in Endocrinology. 2023;19(1):38-45
The incidence of youth-onset type 2 diabetes (T2D) is increasing.1,2 Growing evidence has demonstrated that youth-onset T2D is rapidly progressive, with earlier onset of life-limiting complications compared with adult-onset T2D.3,4 Initiation of effective treatment that can restore beta cell function is critical. Until 2019, metformin and insulin were the only medications approved by the United States […]
Emerging Evidence for the Use of Antidiabetic Drugs, Glucagon-like Peptide 1 Receptor Agonists, for the Treatment of Alzheimer’s Disease
touchREVIEWS in Endocrinology. 2023;19(1):16-24
Type 2 diabetes (T2DM) is a disease with a complex aetiopathogenesis that leads to a wide variety of metabolic disorders. This includes, by definition, high plasma glucose levels, but also elevated blood pressure, dyslipidaemia, cardiorenal complications and strokes. All of these disorders, beyond the progressive beta cell failure, derive from insulin resistance (IR).1 Among the many […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!